USFDA approves Biktarvy label update with data for pregnant adults with HIV: Gilead Sciences Ruchika Sharma28 April 2024 11:30 AM ISTFoster City: Gilead Sciences, Inc. has announced the U.S. Food and Drug Administration (FDA) has approved an updated label with additional data...
Gilead Sciences gets exclusive global license to develop, commercialize Xilio tumor-activated IL-12 Ruchika Sharma31 March 2024 10:00 AM ISTXilio will receive $43.5 million in upfront payments, including a cash payment of $30 million and an initial equity investment by Gilead of $13.5...
Gilead Sciences completes acquisition of CymaBay Therapeutics for USD 4.3 billion Ruchika Sharma24 March 2024 11:00 AM ISTAs a result of the completion of the merger, CymaBay has become a wholly owned subsidiary of Gilead.
Gilead Sciences, Merus collaborate to discover novel antibody-based trispecific T-cell engagers Ruchika Sharma7 March 2024 11:59 AM ISTFoster City: Gilead Sciences, Inc. and Merus N.V. have announced a research collaboration, option and license agreement to discover novel dual...
Expanded Indication for Gilead Biktarvy for HIV with suppressed viral loads, pre-existing resistance gets USFDA okay Ruchika Sharma27 Feb 2024 12:30 PM ISTFoster City: Gilead Sciences, Inc. has announced the U.S. Food and Drug Administration (FDA) has approved a new, expanded indication for Biktarvy...
Gilead Sciences pauses enrollment globally in magrolimab solid tumor studies Ruchika Sharma17 Feb 2024 2:43 PM ISTFoster City: Gilead Sciences, Inc. has announced that it has paused enrollment globally in the magrolimab solid tumor studies. The U.S. Food and Drug...
Gilead Sciences blood cancer therapy trials put on hold by USFDA Ruchika Sharma8 Feb 2024 12:30 PM ISTThe drug is an antibody treatment that blocks a type of protein, called CD47, which helps damaged cells avoid destruction by the immune system.
Gilead Sciences appoints Ted Love to Board of Directors Ruchika Sharma4 Feb 2024 11:00 AM ISTFoster City: Gilead Sciences, Inc. has announced that Ted Love, MD, has been appointed to the company's Board of Directors.Dr. Love is currently...
USFDA approves label update for Kite's Yescarta CAR T-Cell Therapy to include overall survival data Ruchika Sharma26 Dec 2023 12:00 PM ISTSanta Monica: Kite, a Gilead Company has announced that the U.S. Food and Drug Administration (FDA), has approved a label update for Yescarta...
EMA Committee grants positive opinion for Veklury use to treat COVID 19 in people with Hepatic impairment Ruchika Sharma22 Sept 2023 3:30 PM ISTFoster City: Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Gilead Kite declares positive trial results of T-cell Therapy Yescarta in Relapsed/Refractory Large B-cell Lymphoma Ruchika Sharma19 Sept 2023 1:30 PM ISTSanta Monica: Kite, a Gilead Company has announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group...
Gilead Sciences Trodelvy, Keytruda combo study demonstrates promising clinical activity in first-line Metastatic Non-Small Cell Lung Cancer Ruchika Sharma12 Sept 2023 2:30 PM ISTFoster City: Gilead Sciences, Inc. has announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy...
